Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
11:26am, Friday, 29'th Aug 2025
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
09:51am, Thursday, 28'th Aug 2025
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead
06:21am, Wednesday, 27'th Aug 2025
Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. The company
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
12:15pm, Thursday, 21'st Aug 2025
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
10:01am, Tuesday, 19'th Aug 2025
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
11:41am, Sunday, 17'th Aug 2025
Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (CRSP 1.46%), a mid-cap biotech, fits that description.
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
01:02pm, Thursday, 14'th Aug 2025
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025
07:27am, Thursday, 14'th Aug 2025
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain unprofitab
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
12:41pm, Tuesday, 12'th Aug 2025
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
10:01am, Friday, 08'th Aug 2025
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
12:56pm, Tuesday, 05'th Aug 2025
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
Up 50% in 3 Months, Is This Stock Still a Buy?
07:15am, Tuesday, 05'th Aug 2025
Is this finally the year CRISPR Therapeutics (CRSP 6.33%) bounces back? The biotech has lagged the market in recent years, but shares are up 50% over the past three months and have climbed 42% since t
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
06:56pm, Monday, 04'th Aug 2025
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.47. This compares to a loss of $1.49 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
04:15pm, Monday, 04'th Aug 2025
-CASGEVY ® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the pro
New Strong Sell Stocks for August 1st
06:16am, Friday, 01'st Aug 2025
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
